AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05976880 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional treatment along with power ball training
Description: In experimental group, 3sessions per week and total 12 training sessions in a month will be perform. In this session, conventional treatment perform with power ball exercise should be done for 3 minutes in a day, where power ball can initially alleviate the pain, then make them feel strong and in the end persons feel strengthen with pain free movements. Before start training with a power ball, hand held dynamometer will use prior to the first session, on 7th session of training and after 12th training session. So that changes in hand grip strength can be measured by dynamometer.
Study NCT05710614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Animal protein
Description: Patients allocated to this arm will be submitted a supervised resistance training program in combination with the intake of three 15-g daily doses (45g. d- 1 total) animal-based protein (i.e.; whey protein) in drink form as a supplementary source of protein in their main meals of the day.
Study NCT05710614 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plant Protein
Description: Patients allocated to this arm will be submitted a supervised resistance training program in combination with the intake of three 15-g daily doses (45g. d- 1 total) mixed plant protein (i.e.; soy and pea) in drink form as a supplementary source of protein in their main meals of the day.
Study NCT05543226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PHGG-rich enteral nutrtiion
Description: PHGG-rich enteral nutrition
Study NCT04836832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given PO
Study NCT04836832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvelisib
Description: Given PO
Study NCT06727214 — intervention group
Intervention type: DRUG
Intervention: Chemotherapy with platine
Description: medical records that patients received neoadjuvant systemic chemotherapy platine based
Study NCT05880758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent Short Sleep (ISS)
Description: Restricted sleep duration of \<5.5 h/night for 5 nights (SR) followed by 2 nights of 9.5 hours of time in bed (TIB) (recover sleep) each week.
Study NCT05880758 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Jetlag (SJL)
Description: 2-hour delayed sleep timing.
Study NCT05880758 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sustained Adequate Sleep (SAS)
Description: Goal of ≥7 hours of sleep/night with 8 hours of time in bed (TIB).
Study NCT05866159 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape using Rocktape®
Description: Kinesiotape using Rocktape® on day one by a physiotherapist who has experienced more than five years. If possible, the taping will be left for seven days.
Study NCT06523686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Guided bone regeneration
Description: Compare the linear and volumetric bone width changes, clinically and radiographically, between two different bone graft combinations (autogenous-xenogeneic and allogeneic-xenogeneic) covered with a cross-linked collagen membrane in a horizontal GBR.
Study NCT05264662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adacel (Tdap)
Description: Administer Adacel to hiv infected and hiv uninfected pregnant mothers
Study NCT05866159 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham taping
Description: sham taping with Rocktape®, with no tension.
Study NCT05492240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: i-STRONGER
Description: An 8RM is the dose necessary for most effective strength gains in community-dwelling older adults, and is equivalent to 80% of a one repetition max, which is the maximal load needed to voluntarily complete one repetition of a given exercise with proper form. Clinicians will tailor the intervention for each activity, so the patient achieves 8 repetitions with failure on the 9th repetition. Failure is the inability to complete a repetition through the full, available range of motion without significant compensation. Further, high-intensity dosing requires continuous, volitional effort from the patient; therefore, incorporation of motivational interviewing strategies across sessions will maximize patient effort and self-efficacy.
Study NCT05492240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual Care SNFs will continue with routine collection and documentation of physical performance outcomes (gait speed, SPPB, Modified Barthel ADL Index) as standard practice. Furthermore, a combination of chart reviews and on-site or remote observation will allow for characterization of usual care components for descriptive comparison. Importantly, the Usual Care SNF including the facility, rehabilitation clinicians, and patients will not have access to i-STRONGER materials.
Study NCT04838132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral transversus thoracis muscle plane and rectus sheath block with ropivacaine
Description: A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.3% ropivacaine 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
Study NCT04838132 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral transversus thoracis muscle plane and rectus sheath puncture with saline
Description: A linear array transducer (6-13 MHz) with a sterile cover and a 22-gauge (G) block needle (KDL™, Kindly group, Shanghai, China) will be used. Place the ultrasound probe on the longitudinal plane 1 cm outside the edge of the sternum in the fourth intercostal space, and identify the T3-T4 intercostal space under ultrasound. Use the plane technique to place a 22-gauge, 80-mm needle obliquely upwards until the needle tip is located at the plane between the internal intercostal muscles and the transverse pectoralis muscle. After general anesthesia, all subjects were injected with 0.9% saline 15ml and 10ml respectively after insertion of a needle into bilateral transverse thoracic muscle plane and rectus sheath guided by B-ultrasound.
Study NCT06372392 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Universal meal coefficient utilization
Description: Usage of universal fixed meal bolus coefficients for the control of postprandial hyperglycemia compared to individualized coefficients n the users of Medtronic Minimed 780G pumps
Study NCT06372392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Universal meal coefficient utilization
Description: Usage of universal fixed meal bolus coefficients for the control of postprandial hyperglycemia compared to individualized coefficients n the users of Medtronic Minimed 780G pumps
Study NCT06056323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HB0045 Drug Product
Description: Patients will be assigned to dose regimens in the order of enrollment and receive their assigned fixed dose of HB0045 via intravenous infusion, Q3W.
Study NCT04478994 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TEPEZZA
Description: TEPEZZA is a fully human anti-IGF-1R mAb. TEPEZZA will be provided in single-dose 20 mL glass vials as a freeze-dried powder. Each vial of TEPEZZA must be reconstituted with 10 mL of water for injection. Reconstituted TEPEZZA solution must be further diluted in 0.9% (w/v) sodium chloride (NaCl) solution prior to administration. TEPEZZA will be administered in 100 mL or 250 mL infusion bags (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
Study NCT04478994 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will consist of normal saline (0.9% NaCl) solution and will be administered in 100 mL or 250 mL infusion bags, as would be appropriate, per weight-based dosing volumes (100 mL infusion bags for doses up to 1800 mg and 250 mL infusion bags for doses > 1800 mg).
Study NCT04934371 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation (tDCS)
Description: TDCS is a procedure that sends weak electrical currents between points on the scalp. Some of this current flows through the brain, and may induce temporary changes in brain activity lasting 30-60 minutes beyond the time of stimulation. TDCS is believed to be very low risk. TDCS has been applied in more than 4900 studies and hundreds of people to treat various neurological and psychiatric conditions, including depression, epilepsy, chronic pain and Parkinson's. In this study we will use tDCS to suppress symptom of tinnitus and hyperacusis.
Study NCT04969146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic Intervention
Description: The patient and caregiver dyads will complete and return baseline questionnaires and then be randomized to Modified CBTi Dyadic Intervention. The patient and caregiver in the dyadic intervention will have 5 sessions of Modified CBTi. Upon completion of the intervention, the patient and caregiver will complete the follow up assessments at approximately 3 months and 6 months after the baseline questionnaires.
Study NCT04934371 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TDCS
Description: Sham control will be administered to the same area as active TDCS
Study NCT06491719 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NCR300（Allogenic Ipsc-derived Natural Killer cells ）
Description: Patients will receive iNK cells i.V. infusion at 1.0x10\^8/kg on days +14d, +21d, +28d, and +35d post-transplant.~Continuation of the infusion after +35d post-transplant is at the discretion of the physician based on the patient's benefit.
Study NCT04969146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Only Intervention
Description: The patient and caregiver dyads will complete and return baseline questionnaires and then be randomized to Modified CBTi Patient Only Intervention. The patient in the Patient Only Intervention will have 5 sessions of Modified CBTi. Upon completion of the intervention, the patient and caregiver will complete the follow up assessments at approximately 3 months and 6 months after the baseline questionnaires.
Study NCT06344728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib Oral Solution
Description: Brensocatib solution
Study NCT06344728 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brensocatib Oral Tablet
Description: Brensocatib tablet
Study NCT04973072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: One large reward treatment
Description: Participants will be awarded S$300 for reaching the PBF goal at the end of 12 weeks.
Study NCT04973072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Small wins treatment
Description: The cash rewards that participants will receive are capped by $300 and depend on which IGs they achieve and whether they maintain their progress at the end of the 12 weeks. Specifically, given the PBF goal, the Loss Target (LT) is the difference between the initial PBF measured at the first visit and the PBF goal, i.e., LT = initial PBF - PBF goal. Then, the IG1 is to achieve 25% of the LT, the IG2 is to achieve 50% of the LT, and the IG3 is to achieve 75% of the LT. Participants will earn $75 credits to their accounts on the programme website for reaching each intermediate goal. Also, when they miss IG1 and/or IG3, they can earn the previous missing $75 credits if they reach the IG2 and the LT. At the end of the 12 weeks, they will lose some or all the credits that they have accumulated if they fail to maintain the progress, and they will only receive the corresponding amount in cash
Study NCT05044286 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT05637372 — intervention group
Intervention type: RADIATION
Intervention: CBCT
Description: CBCT scan
Study NCT04890249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational IOL Model C1V000
Description: IOL replaces the natural lens removed during cataract surgery.
Study NCT04890249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational IOL Model C2V000
Description: IOL replaces the natural lens removed during cataract surgery.
Study NCT04890249 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control IOL Model ICB00
Description: IOL replaces the natural lens removed during cataract surgery.
Study NCT05354999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate and caffeine
Description: On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.
Study NCT05354999 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sodium bicarbonate and caffeine
Description: On experimental days subjects ingest a combination of sodium bicarbonate, caffeine and placebo.
Study NCT06516653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VasQ
Description: External support implant for the arteriovenous fistula
Study NCT06516653 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula creation for dialysis vascular access
Description: End to side fistula creation in the arm for dialysis vascular access
Study NCT06516653 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arteriovenous fistula creation for dialysis vascular access
Description: End to side fistula creation in the arm for dialysis vascular access
Study NCT06086106 — intervention group
Intervention type: PROCEDURE
Intervention: caudal block
Description: The caudal block involves the injection of a local anesthetic Bupivacaine dose of 0.75 to 1 ml/kg the maximum volume was 10 mL with 0.25% concentration into the caudal epidural space, targeting the sacral nerve roots. to provide a high effect and duration of analgesia
Study NCT04962191 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Idylla EGFR Mutation Test
Description: This diagnostic test is performed on the BioCartis Idylla System for qualitative detection of exon mutations.
Study NCT05373017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DANE Recovery Program
Description: Virtual visits with care coordinator to carry out an individualized recovery plan
Study NCT05307354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tibial Nerve Mobilization
Description: The person performing tibial nerve mobilization will start mobilization by keeping the lower extremity in a horizontal position, with the patient's hip and knee in 45° flexion and ankle in neutral position. Then, in order to mobilize the tibial nerve better, the patient will bring the patient's toes to the extension position, the ankle to the dorsiflexion and eversion position, and the knee joint to the extension to provide appropriate stabilization. Finally, while the patient is in this position, mobilization will be completed by plantar flexion of the distal ankle and flexion of the toes to allow the nerve to slide further distally. This mobilization technique will be performed by an experienced physician/physiotherapist twice a week for 4 weeks, and the patients will be given 5 sets of 10 cycles with a 1-minute rest period in each set.
Study NCT05307354 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Foot-ankle range of motion exercises
Description: In exercise program, foot-ankle joint range of motion exercises will be given. In our study, all exercises will be explained and performed once under the supervision of a physiotherapist, and then the participants will be asked to do all exercises with 10 repetitions, 3 times a day, for four weeks, without the supervision of a physiotherapist.
Study NCT05307354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foot-ankle range of motion exercises
Description: In exercise program, foot-ankle joint range of motion exercises will be given. In our study, all exercises will be explained and performed once under the supervision of a physiotherapist, and then the participants will be asked to do all exercises with 10 repetitions, 3 times a day, for four weeks, without the supervision of a physiotherapist.
Study NCT05373017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: DANE Recovery Program
Description: Virtual visits with care coordinator to carry out an individualized recovery plan
Study NCT04295525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400 mg mucoadhesive oral tablet
Description: AqualiefTM (Metis Healthcare s.r.l., Milano, Italy)
Study NCT04295525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo mucoadhesive oral tablet
Description: placebo
Study NCT05373017 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Questionnaires
Description: Physical, cognitive, and psychological assessments
Study NCT05026749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZM Group
Description: AZM at 20 mg/kg will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
Study NCT05026749 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Saline will be given intravenous daily for 3 days once patients are consented and enrolled into the study.
Study NCT05481775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib 8mg qd po. Taking anlotinib daily for 2 weeks and stop for 1 week.
Study NCT05258500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ghostly app
Description: For the Ghostly app, we include three different trainings (standard, cluster set 1, cluster set 2). The standard training consists of three sets in which twelve muscle contractions are performed with 120 seconds of rest between each set. Each set of twelve contractions will be considered as one level in the game that needs to be ended before taking rest of 120s. Subsequently, the 'Cluster set 1' training is based on the training modalities of cluster set training since evidence shows that similar results can be obtained using cluster set training compared to standard training. The Cluster sets 1 and 2 also consist of 3 sets of twelve repetitions, but with ten seconds of rest between each contraction or 30 seconds of rest after three consecutive contractions respectively. The intensity at which will be trained is 75% of maximum voluntary contraction.
Study NCT05258500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction
Description: Patients will complete four sets of 15 repetitions, with each contraction lasting three seconds. Similar to the first experimental group and control group, the training intensity will be set at 100%MVC with two minutes of rest between sets. The cuff pressure will be set at 50% of arterial occlusion pressure.
Study NCT05258500 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Leaflet
Description: This training program will be matched with the Ghostly game in terms of repetitions, sets and inter-set rest and will be given to the patient to complete without supervision of the therapist.
Study NCT05481775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Docetaxel 25mg/m2 + Cisplatin 25mg/m2 QW
Study NCT05481775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Docetaxel 25mg/m2 + Cisplatin 25mg/m2 QW
Study NCT05481775 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Thoracic radiotherapy was delivered using the daily image-guided intensity modulated radiation therapy (IMRT) technique. The total radiation dose was 66-68 Gy to the gross tumor in 17-22 daily fractions.
Study NCT05481775 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Thoracic radiotherapy was delivered using the daily image-guided intensity modulated radiation therapy (IMRT) technique. The total radiation dose was 66-68 Gy to the gross tumor in 17-22 daily fractions.
Study NCT05481775 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immunotherapy
Description: consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)
Study NCT05481775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: consolidation Immunotherapy (Tislelizhu 200mg iv. drip, Q3W, up to 12 months.)
Study NCT05168033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery training
Description: Mentally imagine to perform rehabilitation exercises or sport-specific tasks without generating actual motor output.
Study NCT05168033 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classic rehabilitation
Description: Classic rehabilitation after anterior cruciate ligament reconstruction focusing on regaining mobility, stability and strength of the knee joint and return to sport.
Study NCT05168033 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classic rehabilitation
Description: Classic rehabilitation after anterior cruciate ligament reconstruction focusing on regaining mobility, stability and strength of the knee joint and return to sport.
Study NCT06005740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TORL-4-500
Description: antibody drug conjugate
Study NCT04949269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucravacitinib
Description: Specified dose on specified days
Study NCT06138041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous lidocaine infusion
Description: Lidocaine bolus of 2mg/kg after induction , and then continuous infusion with 2 mg/kg/h until the participate transfer out of postoperative anesthesia care unit.